Meeting
2016 ASCO Annual Meeting
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
Authors
Vassiliki Papadimitrakopoulou
The University of Texas MD Anderson Cancer Center, Houston, TX
Vassiliki Papadimitrakopoulou , Federico Cappuzzo , Robert M. Jotte , Martin Reck , Tony Mok , Alan Sandler , Daniel Waterkamp , Shelley Coleman , Yasuo Sugitani , Mark A. Socinski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02367781, NCT02367794, NCT02657434, NCT02366143
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS9103)
DOI
10.1200/JCO.2016.34.15_suppl.TPS9103
Abstract #
TPS9103
Poster Bd #
424a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.
First Author: Howard Jack West
Poster
2024 ASCO Annual Meeting
J-TAIL-2: A prospective observational study of atezolizumab (atezo) combination therapy in patients (pts) with non-small cell lung cancer (NSCLC) in Japan.
First Author: Yasutaka Watanabe
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao